000K utf8 1100 2020$c2020-02-04 1500 eng 2050 urn:nbn:de:hbz:464-20200622-152150-8 2051 10.3390/cancers12020353 3000 Metzenmacher, Martin 3010 Aigner, Clemens 3010 Bielefeld, Nicola 3010 Cima, Igor 3010 Forster, Jan 3010 Hegedüs, Balazs 3010 Horn, Peter A. 3010 Klein, Christoph 3010 Kunzmann, Volker 3010 Lueong, Smiths S. 3010 Reis, Henning 3010 Rösch, Alexander 3010 Scheffler, Björn 3010 Schramm, Alexander 3010 Schuler, Martin 3010 Siveke, Jens T. 3010 Szarvas, Tibor 3010 Váraljai, Renáta 3010 Wiesweg, Marcel 4000 Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer [Metzenmacher, Martin] 4209 Early detection of cancer holds high promise for reducing cancer-related mortality. Detection of circulating tumor-specific nucleic acids holds promise, but sensitivity and specificity issues remain with current technology. We studied cell-free RNA (cfRNA) in patients with non-small cell lung cancer (NSCLC; n = 56 stage IV, n = 39 stages I-III), pancreatic cancer (PDAC, n = 20 stage III), malignant melanoma (MM, n = 12 stage III-IV), urothelial bladder cancer (UBC, n = 22 stage II and IV), and 65 healthy controls by means of next generation sequencing (NGS) and real-time droplet digital PCR (RT-ddPCR). We identified 192 overlapping upregulated transcripts in NSCLC and PDAC by NGS, more than 90% of which were noncoding. Previously reported transcripts (e.g., HOTAIRM1) were identified. Plasma cfRNA transcript levels of POU6F2-AS2 discriminated NSCLC from healthy donors (AUC = 0.82 and 0.76 for stages IV and I-III, respectively) and significantly associated (p = 0.017) with the established tumor marker Cyfra 21-1. cfRNA yield and POU6F2-AS transcript abundance discriminated PDAC patients from healthy donors (AUC = 1.0). POU6F2-AS2 transcript was significantly higher in MM (p = 0.044). In summary, our findings support further validation of cfRNA detection by RT-ddPCR as a biomarker for early detection of solid cancers. 4950 https://doi.org/10.3390/cancers12020353$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:hbz:464-20200622-152150-8$xR$3Volltext$534 4961 https://duepublico2.uni-due.de/receive/duepublico_mods_00071462 5051 610 5550 cancer 5550 cfRNA 5550 ddPCR 5550 early detection 5550 liquid biopsy 5550 NGS 5550 POU6F2-AS2